Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Bladder Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

Published in Bladder Cancer

Expert Opinion / Conference Coverage · September 29, 2022

Perioperative Immunotherapy for High-Risk Muscle-Invasive Urothelial Cancer: Insights From CheckMate 274

Written by
Surish P. Shanmugam MBChB, MSc, RCP(UK) (Medical Oncology)


Additional Info

  1. Bajorin DF, Witjes JA, Gschwend JE, et al. Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. N Engl J Med. 2021;384(22):2102-2114.
  2. Necchi A, Bajorin DF, Tomita Y, et al. Tumor and immune features associated with disease-free survival with adjuvant nivolumab in the phase III CheckMate 274 trial. Ann Oncol. 2022;33 (suppl 7):S1331.
  3. Pulido EG, Galsky MD, Van Elzen R, et al. PD-L1 expression on immune cells by SP142 co-localises with dendritic cells and is associated with improved overall survival (OS) with atezolizumab in patients with untreated metastatic urothelial cancer (mUC). Ann Oncol. 2022;33 (suppl 7):S1329.
  4. Patel S, Othus M, Prieto V, et al. Neoadjuvant versus adjuvant pembrolizumab for resected stage III-IV melanoma (SWOG S1801). Ann Oncol. 2022;33 (suppl 7):S1408.
  5. Bex A, Uzzo R, Karam JA,, et al. IMmotion010: Efficacy and safety from the phase III study of atezolizumab (atezo) vs placebo (pbo) as adjuvant therapy in patients with renal cell carcinoma (RCC) at increased risk of recurrence after resection. Ann Oncol. 2022;33 (suppl 7):S1431-S1432.
  6. Motzer RJ, Russo P, Gruenwald V, et al. Adjuvant nivolumab plus ipilimumab (NIVO+IPI) vs placebo (PBO) for localized renal cell carcinoma (RCC) at high risk of relapse after nephrectomy: results from the randomized, phase III CheckMate 914 trial. Ann Oncol. 2022;33 (suppl 7):S1430.
  7. Allaf M, Kim SE, Harshman LC, et al. Phase III Randomized Study comparing Perioperative nivolumab (nivo) versus observation in patients (Pts) with Renal cell carcinoma (RCC) undergoing nephrectomy (PROSPER, ECOG-ACRIN EA8143), a National Clinical Trials Network trial. Ann Oncol. 2022;33 (suppl 7):S1432-S1433.
  8. Powles T, Csőszi T, Özgüroğlu M, et al. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(7):931-945.
  9. Galsky MD, Arija JÁA, Bamias A, et al. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395(10236):1547-1557.
  10. Galsky MD, Guan X, Banchereau R, et al. Cisplatin (cis)-related immunomodulation and efficacy with atezolizumab (atezo) + cis- vs carboplatin (carbo)-based chemotherapy (chemo) in metastatic urothelial cancer (mUC). Ann Oncol. 2021;32 (suppl 5):S682-S683.

Disclosure statements are available on the authors' profiles:

Further Reading